Bart L Scott

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 119:2657-64. 2012
  2. ncbi Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML
    Bart Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 45:2409-17. 2004
  3. ncbi Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 149:706-10. 2010
  4. ncbi Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
    Bart L Scott
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Br J Haematol 148:944-7. 2010
  5. ncbi Myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109, USA
    Annu Rev Med 61:345-58. 2010
  6. ncbi Management of myelodysplastic syndromes: 2008 update
    Bart L Scott
    University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Oncology (Williston Park) 22:1344-52. 2008
  7. ncbi Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:2681-6. 2008
  8. ncbi Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:799-806. 2008
  9. ncbi Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia
    Bart L Scott
    Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:345-54. 2007
  10. ncbi Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006

Research Grants

  1. Improving Allogenic Transplant Outcomes in Myeloid Malignancies
    Bart Scott; Fiscal Year: 2007

Detail Information

Publications20

  1. ncbi The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 119:2657-64. 2012
    ..5 years for intermediate-2 and high-risk patients, respectively. Thus, HCT was curative for a large proportion of patients with myelofibrosis, and post-HCT success was dependent on pre-HCT DIPSS classification...
  2. ncbi Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML
    Bart Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 45:2409-17. 2004
    ..New concepts of conditioning regimens are needed which reduce toxicity without increasing the risk of relapse...
  3. ncbi Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 149:706-10. 2010
    ..Thus, combination therapy with ATG and etanercept was active and safe in patients with MDS...
  4. ncbi Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
    Bart L Scott
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Br J Haematol 148:944-7. 2010
    ..The overall response rate was 72%; median duration of response was not reached at 2 years. Marrow response rates and duration were improved with azacitidine + etanercept compared to azacitidine alone...
  5. ncbi Myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109, USA
    Annu Rev Med 61:345-58. 2010
    ..The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation...
  6. ncbi Management of myelodysplastic syndromes: 2008 update
    Bart L Scott
    University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Oncology (Williston Park) 22:1344-52. 2008
    ....
  7. ncbi Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:2681-6. 2008
    ..7; P = .02). This analysis confirmed that FCSS scores are predictive of posttransplantation outcomes in patients with MDS even after adjusting for risk factors such as marrow myeloblast percentage and IPSS score...
  8. ncbi Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:799-806. 2008
    ..94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT...
  9. ncbi Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia
    Bart L Scott
    Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:345-54. 2007
    ....
  10. ncbi Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  11. ncbi Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities
    Hesham Eissa
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:908-15. 2011
    ..0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease...
  12. ncbi Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 25:4246-54. 2007
    ..Refined risk stratification is required to design prospective trials...
  13. ncbi Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Biol Blood Marrow Transplant 11:65-73. 2005
    ..Further studies that randomize patients to IC versus no IC need to appropriately address the possible beneficial effect of IC...
  14. ncbi Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 120:1398-408. 2012
    ..Although mortality declined significantly in recent years, novel strategies are needed to overcome the barrier of high-risk cytogenetics...
  15. ncbi Hemopoietic cell transplantation for the myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Arch Immunol Ther Exp (Warsz) 53:297-307. 2005
    ..Autologous stem cell transplantation may be beneficial for selected patients who have obtained complete remissions with conventional chemotherapy...
  16. ncbi Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:355-65. 2007
    ..04), and decreased comorbidity score (P = .03) remained statistically significant for improved survival. Our findings show that hematopoietic cell transplantation offers potentially curative treatment for patients with ICMF, PV, or ET...
  17. ncbi Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS
    Aaron T Gerds
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA, USA
    Biol Blood Marrow Transplant 18:1211-8. 2012
    ....
  18. ncbi Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions
    Aaron T Gerds
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, 1100 Fairview Avenue N, D1 100, Seattle, WA, 98109 1024, USA
    Curr Hematol Malig Rep 7:292-9. 2012
    ..We review here contemporary and critical new findings driving current treatment decisions...
  19. ncbi Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Chunkang Chang
    Department of Hematology, Shanghai Sixth People s Hospital, Shanghai Jiaotong University, Shanghai, People s Republic of China
    Blood 110:1379-87. 2007
    ..The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied...
  20. ncbi Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
    Ginna G Laport
    Stanford University Medical Center, Stanford, California 94305 5623, USA
    Biol Blood Marrow Transplant 14:246-55. 2008
    ..Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure...

Research Grants2

  1. Improving Allogenic Transplant Outcomes in Myeloid Malignancies
    Bart Scott; Fiscal Year: 2007
    ..Relevance: The goal of this proposal is to improve survival and quality of life in patients with leukemia and related diseases by developing safer and more effective transplant options. ..